



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

On April 8, 2002

TOWNSEND and TOWNSEND and CREW LLP

By: Joy M. Marshall

#10/B
gnd
4/22/02
PATENT
Attorney Docket No.: 018623-006250US
Client Ref. No.: EPI 0062.50

RECEIVED

APR 18 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SETTE *et al.*

Application No.: 09/707,738

Filed: November 6, 2000

For: INDUCTION OF IMMUNE
RESPONSE AGAINST DESIRED
DETERMINANTS

Examiner: DeCloux, Amy M.

Art Unit: 1644

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

U.S. Patent and Trademark Office
Box SEQUENCE
P.O. Box 2327
Arlington, VA 22202

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action mailed March 19, 2002, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.